Traders should monitor upcoming Phase 1 data readouts for ERAS-0015 (H1 2026) and ERAS-4001 (H2 2026) as key catalysts. The expanded China rights and strong IP protection enhance long-term optionality, but near-term valuation remains dependent on clinical execution.
Price Chart
Executive Summary
Erasca reported fourth quarter and full year 2025 financial results, highlighted by reduced net losses and a strong cash position bolstered by a $259 million financing in January 2026. The company emphasized early clinical progress in its RAS-targeting pipeline, including partial responses for ERAS-0015 across multiple tumor types, and expanded its licensing rights globally. Phase 1 data for ERAS-0015 and ERAS-4001 are expected in H1 and H2 2026, respectively.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year prior.
- Completed upsized public offering in January 2026, raising $258.8 million in gross proceeds, bringing pro forma cash to $434 million.
- Cash expected to fund operations into H2 2028.
- Net loss decreased to $29.1 million in Q4 2025 from $32.2 million in Q4 2024; full-year net loss improved to $124.5 million from $161.7 million in 2024.
- R&D expenses declined to $92.9 million in 2025 from $115.4 million in 2024.
- Promising early clinical activity for ERAS-0015, including confirmed partial responses in multiple RAS-mutant tumors with favorable safety and pharmacokinetics.
- Expanded ERAS-0015 licensing agreement with Joyo Pharmatech to include China, Hong Kong, and Macau, securing worldwide rights.
- U.S. composition-of-matter patents issued for ERAS-0015 (until Sept 2043) and ERAS-4001 (until June 2043).
- Phase 1 monotherapy data for ERAS-0015 expected in H1 2026; ERAS-4001 data expected in H2 2026.
Financial Impact
Reduced R&D and G&A expenses contributed to a $37.1 million improvement in net loss year-over-year; $258.8 million financing significantly strengthens near-term financial runway.
Risk Factors
- Early clinical data are preliminary and may not translate into confirmed responses or regulatory approval.
- Despite improved cash position, the company remains pre-revenue with significant future funding needs dependent on clinical progress.
- Forward-looking statements about timelines and financial runway are subject to delays and higher-than-expected costs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255076 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $17.60 $15.55 | ▼ −11.65% | ▼ −12.96% | $14.94 (−15.09%) |
Aug 17, 2026 6w ago | 144 | $18.28 $16.16 | ▼ −11.60% | ▼ −10.07% | $14.94 (−18.24%) |
Aug 13, 2026 7w ago | Institutional Cluster | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 12, 2026 7w ago | 3 | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 11, 2026 7w ago | Press Release | $18.58 $16.03 | ▼ −13.72% | ▼ −11.83% | $14.94 (−19.56%) |
Jul 22, 2026 10w ago | Press Release | $19.51 $18.07 | ▲ +7.38% | ▲ +10.28% | $14.94 (+23.40%) |
Jul 14, 2026 11w ago | 8-K | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | 424B5 | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | Press Release | $19.50 $18.31 | ▲ +6.10% | ▲ +8.59% | $14.94 (+23.36%) |
Jul 13, 2026 11w ago | Press Release | $19.50 $18.31 | ▼ −6.10% | ▼ −8.59% | $14.94 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access